Charles Chiu

Clinical metagenomic NGS testing for diagnosis of infections! Two papers from my lab support its routine use in hospitalized patients rdcu.be/dZWbb and as a pandemic detection tool rdcu.be/dZWb3 @UCSFHospitals @NatureMedicine @NatureComms @Chiulab_UCSF @UCSF

Thrilled to be part of the 25th PMWC - Precision Medicine World Conference 2026, taking place March 4–6, at the Santa Clara Convention Center in California, co-hosted by Stanford, UCSF & Yale. My session, “Metagenomic Diagnostics & Global Pathogen Surveillance,” is part of Track 3: Next-Gen Early Detection & AI Diagnostics on March 4. I’ll be joining leading experts to explore how metagenomic sequencing is poised to transform medicine and public health by enabling earlier, more accurate, and actionable diagnosis of infectious diseases and strengthening global pathogen surveillance. PMWC 2026, Mar 4-6, will feature over 400 speakers, including Nobel Laureates Mary Brunkow and W.E. Moerner, OpenAI's President & Co-Founder, FDA Commissioner (Fmr), Judy Faulkner (Epic), Carl June (UPenn), David Sinclair (Harvard) & more. Speakers: PMWCintl.com/Speakers Program: PMWCintl.com/Program I look forward to connecting at #PMWC26 Register for PMWC 2026 using my personal code: lnkd.in/g-neMVea @PMWCintl

Making mNGS testing more widely available is critical for improving infectious disease diagnosis. Proud to be part of the @DelveBio team in partnership with @UCSF working to make this technology more accessible to patients everywhere! businesswire.com/news/home/2024…

In the companion @naturecomms paper on viral respiratory mNGS testing, we demonstrate that in the future, mNGS detection of any pandemic virus is possible, no matter how sequence-divergent, based on homology to related animal and/or plant viruses. rdcu.be/dZWb3

Clinical metagenomic NGS testing for diagnosis of infections! Two papers from my lab support its routine use in hospitalized patients rdcu.be/dZWbb and as a pandemic detection tool rdcu.be/dZWb3 @UCSFHospitals @NatureMedicine @NatureComms @Chiulab_UCSF @UCSF

The story of my life, published as a biographical feature by @ASMicrobiology! A shout-out to @GreningerLab @EBabady @climberkip @Astro_Kate7 @VanNuysHigh who are mentioned in the article. @UCSF @UCSFHospitals @UCSFPrecision @Chiulab_UCSF journals.asm.org/doi/10.1128/jc…

Our 7-year experience with clinical Metagenomic next-generation sequencing of spinal fluid for dx of CNS infections. The test was used to diagnose infections in nearly 1000 patients! New and Improved Option for Detecting Neurologic Pathogens? medscape.com/viewarticle/ne…

@TheBradOwen @WPT Are you in the upper half in chop counts?

I made the money and Day 3 of the @WPT World Championship! I bagged 310k and we come back with 36 mins left of 10k/15k. 480 players remain, we’ve got $18.7k locked up and the dream is still alive for the $5.68 million 1st place prize!

A single read that prompted a nationwide CDC investigation! Please read about another win for CSF mNGS at UCSF. @UCSFHospitals @UCSFPrecision @UCSF_Catalyst @Chiulab_UCSF @dmaccannell @Bob_Wachter thelancet.com/journals/lanmi…

Hi everyone, I am excited to introduce Delve Bio to you, a startup using the metagenomic next-gen sequencing platform that we developed at UCSF to diagnose infections! @UCSFPrecision @ucsfhealth @Chiulab_UCSF @UCSF_Catalyst #mNGS bloomberg.com/news/articles/… via @business

Our Nature study on AAV2 and multiple co-infections in cases of acute severe hepatitis in children was highlighted in the New York Times: nature.com/articles/s4158… nytimes.com/2023/03/30/hea…

Our latest study @mammothbiosci in collaboration with @cychiu98 @UCSF is now online at @ASMicrobiology Journal of Clinical Microbiology! We programmed our #CRISPR-based DETECTR platform to rapidly detect #COVID-19 Variants 🧪🧬 journals.asm.org/doi/full/10.11…

This is amazing," The genome sequences will be further curated (to refine low coverage regions, indels & homopolymeric tracts) as soon as high depth Illumina data is available (sequencing ongoing)." Sharing data as it is being produced, a new level of scientific data sharing 🇵🇹

Our #SARSCoV2 #COVID19 paper on limited cross-variant immunity in unvaccinated individuals vs Omicron is out in Nature. Please get vaccinated! @TheOttlab @doudna_lab @Chiulab_UCSF Limited cross-variant immunity from SARS-CoV-2 Omicron without vaccination nature.com/articles/s4158…

Excellent talk from ⁦@cychiu98⁩ on ngs & the physician perspective - sometimes interesting things lurk below the threshold. Wish talks were a bit longer so we could delve into how much junk might be in there too… great session so far though! #CVS22 ⁦@ASMicrobiology⁩

say hello to our newest Chiu lab scientist, Baby Geny!

How have @CDCgov @CDC_AMD Broad Agency Announcements helped to bolster national genomic surveillance and response? Some great examples from @cychiu98 @UCSF, Mike Garrett @UMMCnews, Heba Mostafa @HopkinsMedicine and others. #SPHERES cdc.gov/amd/whats-new/…

🆕 @CellCellPress Omicron breakthrough infections induce a weak neutralizing antibody response, ~1/10 that of Delta, 1/3 of a booster shot, "suggesting reduced protection vs infection or a future variant" cell.com/cell/fulltext/… @cychiu98 @TheOttLab @UCSFMedicine @GladstoneInst

Why is it that we never learn our lesson? Influenza H1N1, Zika, Ebola, SARS-CoV2… we are always being reactive, not proactive. apple.news/AJMG_zD8DTo2fj…

@RustyShack88 @CarlosdelRio7 @K_G_Andersen @ScottGottliebMD @RustyShack88 @CarlosdelRio7 @K_G_Andersen @ScottGottliebMD please note that these other published studies looked at Delta (or earlier variant) breakthrough infections rather than Omicron breakthrough infections.

Other data show antibody response after Omicron may not be as robust as seen with delta. While there are other components of immunity, taken together, suggests period of immunity from infection conferred by Omicron might not be as persistent as some hoped medrxiv.org/content/10.110…